Phase 2 study of XProTM will be a six-month, blinded, randomized, placebo-controlled trial in 168 patients with mild Alzheimer’s disease and biomarkers of inflammation.
Additional analysis from the Phase 1b study of XProTM demonstrates improvements in white matter analytics within three months in all patients treated with 1.0 mg/kg which supports the dose and duration of the Phase II trial.
Recent $40 million financing provides runway to Phase 2 Alzheimer’s data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.